Zacks downgraded shares of Protalix BioTherapeutics (NYSE:PLX) from an outperform rating to a neutral rating in a research note released on Thursday morning, ARN reports. They currently have $5.90 target price on the stock.
Zacks has also modified their ratings on a number of other healthcare stocks in the few days. The firm reiterated its neutral rating on shares of Check Point Software. They have a $59.00 price target on that stock. Also, Zacks downgraded shares of Netease.com from an outperform rating to a neutral rating. Their analysts now have a $68.90 price target on that stock. Finally, Zacks upgraded shares of Euroseas Ltd. from an underperform rating to a neutral rating. Zacks now has a $1.20 price target on that stock.
Shares of Protalix BioTherapeutics (NYSE: PLX) traded down 0.53% during mid-day trading on Thursday, hitting $5.61. Protalix BioTherapeutics has a 52 week low of $4.68 and a 52 week high of $6.73. The stock’s 50-day moving average is currently $5.16. The company’s market cap is $517.2 million.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
To view Zacks’ full report, visit www.zacks.com